Rose Higgins
Chief Executive Officer
Rose brings a long and successful track record in executive management and leadership along with extensive experience in strategic sales and marketing, product development, project management and clinical practice to HealthMyne. Her prior work includes time with Cardinal Health (Pyxis), iMetrikus, McKesson, and most recently she served as President of SCIO Health Analytics which was acquired by EXL Services.
John Pins
Chief Financial Officer
John is an operationally-focused executive with over 20 years of experience in healthcare technology finance. Over the course of his career, he has worked closely with operating teams on aggressive growth initiatives including strategic acquisitions, new product development, and global business and revenue expansion. John is a CPA and received his BA in Accounting from Iowa State University.
Career Highlights:
- 18 years at Wolters Kluwer; worked in a Public Accounting firm as his first job
- Vice President, Finance at Wolters Kluwer Health from 2006-2015. Reported to the CEO (AS)
- Vice President, Controller at Blue Cross & Blue Shield of Kansas City prior to joining HealthMyne
Michele Norton, MS, RN, INS
Chief Marketing Officer
Michele Norton has over 25 year’s experience in healthcare across many facets of the industry including health systems, ACOs, payer and life sciences organizations. She brings considerable experience and expertise in marketing and product strategy as well as optimization of clinical technology and analytics solutions and services.
Prior to joining HealthMyne she held various senior executive positions leading marketing and product strategy at SCIO Health Analytics, Zynx Health and McKesson Corporation. Her clinical and informatics background provides her with a unique perspective on the impact data and technology can have on care quality and outcomes. Michele received her Bachelor of Science in Nursing with honors from the University of Florida and her Master of Science in Nursing with a healthcare informatics specialty from the University of Colorado Health Sciences Center.
Robert Holmes, Ph.D.
Chief Science Officer
Dr. Holmes has over 25 years’ experience in the successful application of machine learning and advanced analytics to a range of commercial and industrial problems. Since 2004 he has been working exclusively in the healthcare sector, where he has delivered solutions to pharmaceutical clients, healthcare delivery systems, and health plans. Throughout his career he has fulfilled dual roles: at an individual level he has brought detailed technical and scientific contributions to projects; whilst at a management level he has developed and led teams of highly performant engineers and scientists to commercialize the results of those projects.
Dr. Holmes received his Master of Arts in Physics from Oxford University, UK and his Ph.D. in Physics from Portsmouth University.
Duane Smulling
Vice President, Sales
Duane is an innovative sales leader with over 25 years’ experience in driving sales strategy and exceeding performance. At HealthMyne he oversees the growth strategy and business development efforts across markets with a focus on Life Sciences. Before joining HealthMyne he was with IPM.ai, an AI/ML company which uses longitudinal medical claims data for better comprehension of rare and cancer conditions, where he led their Life Sciences business development efforts for the mid-Atlantic and Southeast. Prior to IPM.ai, Duane worked at SCIO Health Analytics as AVP Sales (Life Sciences) with responsibility across disease conditions. In addition, Duane has applied his advanced healthcare analytics experience at Veeva, Qforma, FICO and Symphony Health.
Duane received his Bachelor of Business from Temple University and his Master of Organizational Leadership from Cairn University.
Nick West, RT(R)
Director, Customer Success
Nick has over 15 years of industry experience in healthcare with a core focus in radiology. Nick oversees all aspects of customer success, implementation and account management at HealthMyne. Prior to joining HealthMyne he was with Roche and Philips Healthcare. His prior experience includes relevant clinical roles as a clinical transformation consultant, solution application specialist, clinical coordinator, and radiographer. Nick has executed multiple projects delivering rapid clinical adoption and high customer satisfaction. He uses Lean Six Sigma and change acceleration process tools to facilitate formal clinical and operational continuous improvement engagements.
Nick is a Registered Radiologic Technologist, Radiology RT(R) and Six Sigma Black Belt.
T. “Rock” Mackie, Ph.D.
Chairman
Rock is a Director of Medical Devices (part-time) at the Mortgridge Institute for Research in Madison and Emeritus Professor in the departments of Medical Physics, Human Oncology, and Engineering Physics at the UW-Madison. In 1997, Rock co-founded TomoTherapy Inc., which developed an innovative, integrated hardware/software system for accurate, image-guided radiation treatment delivery. TomoTherapy’s initial public offering in 2007 reached a peak market capitalization of over $1.2 B under Rock’s leadership as chairman of the board of directors. Prior to its sale to Accuray, TomoTherapy’s cumulative revenues exceeded $ 1 billion. In 1992, Rock co-founded Geometrics, a HCIT company which developed the PinnacleTM Radiation Treatment Planning (RTP) system, now marketed by Philips Medical Systems. From 1996 until 2012, Pinnacle generated over $350 M in revenues and achieved a 45+% global market share. Rock has a doctorate in Physics from the University of Alberta. He has more than 150 publications and over 30 inventions with issued US patents.
Scott Button, CFA, MBA
Scott is a Managing Director at Venture Investors, a leading provider of seed and early stage venture capital with over $250M in management. Scott joined the firm in 1996 and focuses on investment opportunities in medical devices, digital health, material sciences and information technology. He created the firm’s Venture Igniter program to encourage and support academic and student led start-ups.
Scott currently represents Venture Investors on the Board of Directors for HealthMyne, Silatronix, and NeuWave Medical. He serves on the Board of Advisors for the University of Wisconsin’s Chemistry Department, is a member of the Madison Development Corporation’s Debt Advisory Committee, is a MERLIN Mentor and a frequent guest lecturer at the UW Madison Business and Engineering schools. Prior to joining Venture Investors, Scott worked for McDonald’s Corporation and Rockwell Automation. He is a graduate of the University of Wisconsin-Madison (BS–Mechanical Engineering), The University of Chicago (MBA) and is a Chartered Financial Analyst (CFA).
Mary Margaret (Mimi) Huizinga, MD, MPH
Mary Margaret (“Mimi”) Huizinga, MD, MPH FACP, is Chief Medical Officer and Head of R&D at Rafael Holdings. Dr. Huizinga was previously the Vice President and Head, US Oncology Medical at Novartis where she led clinical development and medical affairs for oncology in the US. Prior to that, she was VP of Strategic Data and Digital for US Oncology at Novartis where she supported the broader digital, data and real-world evidence needs and Novartis’s goal to go big on data and digital.
Before joining Novartis, Dr. Huizinga was the Chief Health Information Officer at Premier, Inc., In addition, she held various executive positions within health systems including the Medical Director for the Center of Health Promotion and Disease Management at Vanderbilt University as well as the Vice President for Quality at LifePoint Hospitals. She is a board-certified internist, a Fellow of the American College of Physicians and a part-time Assistant Professor of Medicine at The Johns Hopkins University School of Medicine.
John Kuelper, J.D., MBA
John Kuelper is a Managing Director at Ascension Ventures, a strategic venture capital and growth equity firm with over $800 million under management which invests in health IT, health services, medical devices and diagnostics on behalf of thirteen of the nation’s largest non-profit health systems. John is Founder and President of Qualia Holdings LLC, a platform for systems biology and software ventures. He has advised or worked for several investment firms (Adams Street Partners, Sterling Partners, Abundant Venture Partners), medical technology companies (Stereotaxis, Orpheden Therapeutics), and non-profits (The Kresge Foundation, the Blue Cross and Blue Shield Association). John began his career as a medical researcher studying computational neuroscience and medical robotics and has over fifteen years of experience as a commercial software developer. John earned JD and MBA degrees from the Northwestern University and a BA in cognitive neuroscience from Washington University in St. Louis. In 2014 he was elected to the Kauffman Fellows Society.
Dan Malven, MBA
Dan has over two decades of operating and venture capital experience. Prior to 4490 Ventures, Dan was investing in early stage software companies at 1347 Ventures. Dan was also previously an executive at Walgreens and the co-founder of three software companies. Dan has a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Sciences in Industrial Engineering from Purdue University.
Pierre P. Massion, MD
HealthMyne is deeply saddened by the passing of Dr. Pierre Massion. A renowned scientist and physician, Dr. Massion was a true advocate for early detection in lung cancer and the role of biomarkers in characterizing tumor biology. The team at HealthMyne is forever grateful to Dr. Massion for his many contributions to the field and to our company.
Dr. Pierre Massion worked in the field of lung cancer biology, early detection, and therapeutics since 1999. He oversaw a rich environment to translate science from the program to trials in the cooperative groups. His laboratory is funded by the NCI and the Veterans Administration to investigate novel strategies for the early detection and molecular characterization of early lung cancer. He published over 170 publications in the areas of lung cancer development, role of oncogenes in the progression of lung tumor cells, and innovative strategies towards the development of molecular biomarkers for early detection of lung cancer and intermediate endpoint biomarkers of response to chemoprevention. In recognition of his work, he was elected a fellow of the American Association for the Advancement of Science. Dr. Massion has mentored over 21 postdoctoral fellows, 11 graduate students and 20 undergraduate students. He was the principal investigator of 8 trials listed on clinicaltrials.gov.
Rivka Colen, MD
Associate Professor Diagnostic Radiology Director of Imaging Genomics, Radiomics & Therapeutics Lab
Dr. Rivka Colen is the Associate Professor in the Department of Diagnostic Radiology at the University of Pittsburgh Medical Center. Dr. Colen is the Director of the Imaging Genomics, Radiomics and Therapeutics Lab, Director of the Imaging Response Assessment Core, Director of the Radiogenomics and Artificial Intelligence Core, and co-Director of the In-Vivo Imaging Facility of the CCSG NIH Cancer Center Grant. Previously, she was an Assistant Professor and then Associate Professor at MD Anderson Cancer Center where she was Director of the Imaging Genomics, Radiomics and Therapeutics Lab and co-Director of the Quantitative Imaging Analysis Core.
Dr. Colen specializes in quantitative imaging analysis/biomarkers and clinical, translational, and preclinical imaging genomics, radiomics, big data and image guided therapy in brain tumors. Dr. Colen has pioneered the field of imaging genomics in brain tumors and published the first paper on quantitative imaging genomics.
Robert J. Gillies, Ph.D.
Dr. Gillies received his PhD in Zoology from UC Davis in 1979. After a post-doctoral appointment at Yale University (1979-1982), he has held faculty positions at Colorado State Univ. (1982-1988), the Univ. of Arizona (1988-2008) and the Moffitt Cancer Center (2008-pres), where he is chair of the Department of Cancer Imaging and Metabolism, vice-chair of Radiology and director of the Center of Excellence in Imaging and Technology.
He has published over 243 peer-reviewed articles in the use of imaging and spectroscopy to interrogate tumor physiology, and is currently PI or co-PI on eight NCI grants or sub-contracts focused on cancer imaging. He has a long-standing interest in detailed image analysis to better describe tumor physiology and, in 2009, he coined the term “Radiomics”. He has been a major contributor to this field ever since, primarily in improved diagnosis of lung and prostate cancer.
Adrian Kilcoyne, MD, MBA
Chief Medical Officer Humanigen
Dr. Adrian Kilcoyne is an experienced Pharmaceutical Professional with significant leadership experience in the Pharmaceutical Industry as well as over 15 years Clinical Experience. In addition to having a strong commercial focus, he has a strong track record of driving performance, building teams, and finding innovative new ways of working. He embraces the future and prepares organizations to be at the forefront of new technologies in data analytics and utilization.
In addition to Dr. Kilcoyne’s medical degree and 2 postgraduate medical qualifications, he holds 2 master’s degrees, an MBA from Warwick Business School and a Master’s in Public Health from the London School of Hygiene and Tropical medicine. He has completed Specialist training in Pharmaceutical Medicine and am a Board-Certified Pharmaceutical Physician.
Mark Lee, MD, PhD
Mark Lee, MD, PhD, is a medical oncologist and most recently served as the Senior Vice President and Global Head for Personalized Healthcare, Product Development at Genentech/Roche where he led the strategic effort to incorporate data-at-scale, real world data, advanced analytics, and digital health technologies into drug development and integrated healthcare solutions. Prior to joining Genentech, Mark was on the founding team and Head of Clinical Development and Medical Affairs at GRAIL, where he built one of the largest clinical research programs in genomic medicine aimed at early cancer detection.
Mark’s previous roles include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays. His prior work also includes tissue-based and molecular imaging biomarker discovery at Genentech. Mark holds a PhD in Biological Chemistry and Molecular Pharmacology from Harvard, and a MD from Stanford University, where he completed his internal medicine training and medical oncology fellowship.
Alvin Silva, MD
Professor of Radiology, Medical Director of Imaging Clinical Outcomes and Response Evaluation Lab
Dr. Alvin Silva is a Professor of Radiology in the Mayo Clinic College of Medicine and Science. His institutional responsibilities at Mayo Clinic include: Member of the Education Committee of the Research Operations Management Team; Chair of the Education Committee – Department of Radiology; Medical Director of Imaging Clinical Outcomes and Response Evaluation Lab; Section Chief of Abdominal Imaging and Body MRI; and Clinical Director of the Body MRI Fellowship.
Dr. Silva has published over 70 peer-reviewed publications along with numerous book chapters, abstracts, and editorials. He is a Diplomate in Radiology of the National Board of Medical Examiners and a Fellow in the Society of Abdominal Radiology. Dr. Silva received his M.D. degree from Wright State University School of Medicine in Dayton.
Carey Thomson, MD, MPH
Director of the Multidisciplinary Lung Cancer Screening and Thoracic Oncology Program, Chief of Pulmonary and Critical Care Medicine at Mount Auburn Hospital, and Associate Professor of Harvard Medical School